EWTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Edgewise Therapeutics reveals the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500Sep 22, 2026
- Servier completed the acquisition of Edgewise Therapeutics' muscular dystrophy businessJul 13, 2026
- Edgewise Therapeutics reported positive topline results from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500Jun 16, 2026
- Edgewise reported positive long-term sevasemten data showing sustained functional stabilization in Becker muscular dystrophy for 3.5 yearsMar 10, 2026
- Edgewise Therapeutics completes EDG-7500 CIRRUS-HCM Phase 2 Parts B and C with favorable interim safety from Part D in hypertrophic cardiomyopathyDec 24, 2025